Mefexamide

Mefexamide is a psychostimulant psychopharmaceutical and aryloxyacetic acid derivative antidepressant with dopaminergic activity. Mefexamide can be used for the research of depression^[1][2]. In Vitro:Mefexamide (1 g; 15 min refluxed) undergoes acid hydrolysis to yield four breakdown products, and the compound exhibits distinct spectroscopic and chromatographic profiles, including a melting point of 112 °C, UV absorption maximum at 285 nm, and characteristic EI/CI mass spectra^[1]. In Vivo:Mefexamide (i.v. perfusion) demonstrates sympathomimetic activity by reversing Reserpine (HY-N0480)-induced ptosis in male Fauve de Bourgogne rabbits^[2].
Mefexamide reverses Tetrabenazine (HY-B0590)-induced ptosis in male Wistar rats^[2].
Mefexamide (5-20 mg/kg; i.v.; singer dose) significantly potentiates LSD-25-induced hyperthermia in male rabbits^[2].
Mefexamide (5-20 mg/kg; i.v.; singer dose) potentiates Noradrenaline (HY-13715)-induced hyperthermia in male rabbits, with less significant effects than seen with LSD-25^[2].
Mefexamide (10 mg/kg; i.v.; singer dose) protects against Reserpine (HY-N0480)-induced lowering of the bemegride convulsion threshold in male rabbits^[2].
Mefexamide (10 mg/kg; i.v.; singer dose) does not significantly alter the EEG of normal male rabbits^[2].